CPA
DNA icon

Capital Performance Advisors’s Ginkgo Bioworks DNA Stock Holding History

Capital Performance Advisors’s Portfolio DNA Stock Details DNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-121
Closed -$986 – 849
2024
Q3 		$986 Buy
+121
New +$1.21K ﹤0.01% 1913

Other funds holding DNA

Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACG
Anchorage Capital Group New York $436M AUM 38.51% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
Legal & General Group
Legal & General Group London, United Kingdom $432B AUM 29.4% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Capital Performance Advisors's DNA Position: Q4 2024 in Review

Capital Performance Advisors sold out of Ginkgo Bioworks (DNA) in Q4 2024, closing a stake of 121 shares — an estimated $986 sold.

Capital Performance Advisors first reported a position in DNA in Q3 2024 and held it in 1 quarter. The position peaked at $986 in Q3 2024. 165 funds tracked by Wall St. Rank hold DNA as of Q4 2024.

  • Capital Performance Advisors reported no remaining Ginkgo Bioworks position as of Q4 2024 after selling out during the quarter.
  • Capital Performance Advisors sold 121 Ginkgo Bioworks shares in Q4 2024, an estimated $986.
  • Capital Performance Advisors first reported a position in Ginkgo Bioworks in Q3 2024 and held it in 1 quarter.
  • Capital Performance Advisors's Ginkgo Bioworks position peaked at $986 in Q3 2024.
  • 165 funds tracked by Wall St. Rank held Ginkgo Bioworks as of Q4 2024.

Based on Capital Performance Advisors's 13F filing for Q4 2024, filed 31 Jan 2025.